We have noticed the emergence of an interesting trend that is popping up in the emerging biopharmaceutical industry: platform technologies, which differ from one company to the next. In Kleo’s case, platform technology essentially involves the engineering of antibodies and biologics using linear process chemistry to enhance drug effectiveness. In this interview, Doug Manion, CEO of Kleo, will explain.
Apr 24 2020 - Apr 29 2020
San Diego Convention Center